Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment

Yanfei L. Ma, Qing Q. Zeng, Alan Y. Chiang, David Burr, Jiliang Li, Harald Dobnig, Astrid Fahrleitner-Pammer, Dana Michalská, Fernando Marin, Imre Pavo, Jan J. Stepan

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Cortical bone, the dominant component of the human skeleton by volume, plays a key role in protecting bones from fracture. We analyzed the cortical bone effects of teriparatide treatment in postmenopausal women with osteoporosis who had previously received long-term alendronate (ALN) therapy or were treatment naïve (TN). Tetracycline-labeled paired iliac crest biopsies obtained from 29 ALN-pretreated and 16 TN women were evaluated for dynamic histomorphometric parameters of bone formation at the periosteal, endocortical and intracortical bone compartments, before and after 24. months of teriparatide treatment. At baseline, the frequency of specimens without any endocortical and periosteal tetracycline labeling, and the percentage of quiescent osteons, was higher in the ALN than the TN group. Endocortical and periosteal mineralizing surface (MS/BS%), periosteal bone formation rate (BFR/BS), mineral apposition rate (MAR) and the number of intracortical forming osteons were significantly lower in the ALN-pretreated patients than in the TN group. Following teriparatide treatment, the frequency of endocortical and periosteal unlabeled biopsies decreased; in the ALN-pretreated group the percentage of quiescent osteons decreased and, in contrast, forming and resorbing osteons were increased. Teriparatide treatment resulted in significant increases of MAR in the endocortical, and MS/BS% in the periosteal compartment in the ALN-pretreated group. Most indices of bone formation remained lower in the ALN-pretreated group compared with the TN group at study end. Endocortical wall width was increased in both ALN-pretreated and TN groups. Cortical porosity and cortical thickness were significantly increased in the ALN-pretreated group after teriparatide treatment. Our results suggest that 24. months of teriparatide treatment increases cortical bone formation and cortical turnover in patients who were either TN or had previous ALN therapy.

Original languageEnglish (US)
Pages (from-to)139-147
Number of pages9
JournalBone
Volume59
DOIs
StatePublished - 2014

Fingerprint

Teriparatide
Alendronate
Haversian System
Therapeutics
Osteogenesis
Tetracycline
Minerals
Biopsy
Porosity
Bone Fractures

Keywords

  • Alendronate
  • Bone biopsy
  • Bone formation
  • Cortical histomorphometry
  • Teriparatide

ASJC Scopus subject areas

  • Physiology
  • Endocrinology, Diabetes and Metabolism
  • Histology

Cite this

Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment. / Ma, Yanfei L.; Zeng, Qing Q.; Chiang, Alan Y.; Burr, David; Li, Jiliang; Dobnig, Harald; Fahrleitner-Pammer, Astrid; Michalská, Dana; Marin, Fernando; Pavo, Imre; Stepan, Jan J.

In: Bone, Vol. 59, 2014, p. 139-147.

Research output: Contribution to journalArticle

Ma, YL, Zeng, QQ, Chiang, AY, Burr, D, Li, J, Dobnig, H, Fahrleitner-Pammer, A, Michalská, D, Marin, F, Pavo, I & Stepan, JJ 2014, 'Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment', Bone, vol. 59, pp. 139-147. https://doi.org/10.1016/j.bone.2013.11.011
Ma, Yanfei L. ; Zeng, Qing Q. ; Chiang, Alan Y. ; Burr, David ; Li, Jiliang ; Dobnig, Harald ; Fahrleitner-Pammer, Astrid ; Michalská, Dana ; Marin, Fernando ; Pavo, Imre ; Stepan, Jan J. / Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment. In: Bone. 2014 ; Vol. 59. pp. 139-147.
@article{6bbfe5379c3c4a4faee2ddf5ca667622,
title = "Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment",
abstract = "Cortical bone, the dominant component of the human skeleton by volume, plays a key role in protecting bones from fracture. We analyzed the cortical bone effects of teriparatide treatment in postmenopausal women with osteoporosis who had previously received long-term alendronate (ALN) therapy or were treatment na{\"i}ve (TN). Tetracycline-labeled paired iliac crest biopsies obtained from 29 ALN-pretreated and 16 TN women were evaluated for dynamic histomorphometric parameters of bone formation at the periosteal, endocortical and intracortical bone compartments, before and after 24. months of teriparatide treatment. At baseline, the frequency of specimens without any endocortical and periosteal tetracycline labeling, and the percentage of quiescent osteons, was higher in the ALN than the TN group. Endocortical and periosteal mineralizing surface (MS/BS{\%}), periosteal bone formation rate (BFR/BS), mineral apposition rate (MAR) and the number of intracortical forming osteons were significantly lower in the ALN-pretreated patients than in the TN group. Following teriparatide treatment, the frequency of endocortical and periosteal unlabeled biopsies decreased; in the ALN-pretreated group the percentage of quiescent osteons decreased and, in contrast, forming and resorbing osteons were increased. Teriparatide treatment resulted in significant increases of MAR in the endocortical, and MS/BS{\%} in the periosteal compartment in the ALN-pretreated group. Most indices of bone formation remained lower in the ALN-pretreated group compared with the TN group at study end. Endocortical wall width was increased in both ALN-pretreated and TN groups. Cortical porosity and cortical thickness were significantly increased in the ALN-pretreated group after teriparatide treatment. Our results suggest that 24. months of teriparatide treatment increases cortical bone formation and cortical turnover in patients who were either TN or had previous ALN therapy.",
keywords = "Alendronate, Bone biopsy, Bone formation, Cortical histomorphometry, Teriparatide",
author = "Ma, {Yanfei L.} and Zeng, {Qing Q.} and Chiang, {Alan Y.} and David Burr and Jiliang Li and Harald Dobnig and Astrid Fahrleitner-Pammer and Dana Michalsk{\'a} and Fernando Marin and Imre Pavo and Stepan, {Jan J.}",
year = "2014",
doi = "10.1016/j.bone.2013.11.011",
language = "English (US)",
volume = "59",
pages = "139--147",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment

AU - Ma, Yanfei L.

AU - Zeng, Qing Q.

AU - Chiang, Alan Y.

AU - Burr, David

AU - Li, Jiliang

AU - Dobnig, Harald

AU - Fahrleitner-Pammer, Astrid

AU - Michalská, Dana

AU - Marin, Fernando

AU - Pavo, Imre

AU - Stepan, Jan J.

PY - 2014

Y1 - 2014

N2 - Cortical bone, the dominant component of the human skeleton by volume, plays a key role in protecting bones from fracture. We analyzed the cortical bone effects of teriparatide treatment in postmenopausal women with osteoporosis who had previously received long-term alendronate (ALN) therapy or were treatment naïve (TN). Tetracycline-labeled paired iliac crest biopsies obtained from 29 ALN-pretreated and 16 TN women were evaluated for dynamic histomorphometric parameters of bone formation at the periosteal, endocortical and intracortical bone compartments, before and after 24. months of teriparatide treatment. At baseline, the frequency of specimens without any endocortical and periosteal tetracycline labeling, and the percentage of quiescent osteons, was higher in the ALN than the TN group. Endocortical and periosteal mineralizing surface (MS/BS%), periosteal bone formation rate (BFR/BS), mineral apposition rate (MAR) and the number of intracortical forming osteons were significantly lower in the ALN-pretreated patients than in the TN group. Following teriparatide treatment, the frequency of endocortical and periosteal unlabeled biopsies decreased; in the ALN-pretreated group the percentage of quiescent osteons decreased and, in contrast, forming and resorbing osteons were increased. Teriparatide treatment resulted in significant increases of MAR in the endocortical, and MS/BS% in the periosteal compartment in the ALN-pretreated group. Most indices of bone formation remained lower in the ALN-pretreated group compared with the TN group at study end. Endocortical wall width was increased in both ALN-pretreated and TN groups. Cortical porosity and cortical thickness were significantly increased in the ALN-pretreated group after teriparatide treatment. Our results suggest that 24. months of teriparatide treatment increases cortical bone formation and cortical turnover in patients who were either TN or had previous ALN therapy.

AB - Cortical bone, the dominant component of the human skeleton by volume, plays a key role in protecting bones from fracture. We analyzed the cortical bone effects of teriparatide treatment in postmenopausal women with osteoporosis who had previously received long-term alendronate (ALN) therapy or were treatment naïve (TN). Tetracycline-labeled paired iliac crest biopsies obtained from 29 ALN-pretreated and 16 TN women were evaluated for dynamic histomorphometric parameters of bone formation at the periosteal, endocortical and intracortical bone compartments, before and after 24. months of teriparatide treatment. At baseline, the frequency of specimens without any endocortical and periosteal tetracycline labeling, and the percentage of quiescent osteons, was higher in the ALN than the TN group. Endocortical and periosteal mineralizing surface (MS/BS%), periosteal bone formation rate (BFR/BS), mineral apposition rate (MAR) and the number of intracortical forming osteons were significantly lower in the ALN-pretreated patients than in the TN group. Following teriparatide treatment, the frequency of endocortical and periosteal unlabeled biopsies decreased; in the ALN-pretreated group the percentage of quiescent osteons decreased and, in contrast, forming and resorbing osteons were increased. Teriparatide treatment resulted in significant increases of MAR in the endocortical, and MS/BS% in the periosteal compartment in the ALN-pretreated group. Most indices of bone formation remained lower in the ALN-pretreated group compared with the TN group at study end. Endocortical wall width was increased in both ALN-pretreated and TN groups. Cortical porosity and cortical thickness were significantly increased in the ALN-pretreated group after teriparatide treatment. Our results suggest that 24. months of teriparatide treatment increases cortical bone formation and cortical turnover in patients who were either TN or had previous ALN therapy.

KW - Alendronate

KW - Bone biopsy

KW - Bone formation

KW - Cortical histomorphometry

KW - Teriparatide

UR - http://www.scopus.com/inward/record.url?scp=84889578208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889578208&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2013.11.011

DO - 10.1016/j.bone.2013.11.011

M3 - Article

C2 - 24269280

AN - SCOPUS:84889578208

VL - 59

SP - 139

EP - 147

JO - Bone

JF - Bone

SN - 8756-3282

ER -